Numerous publications have highlighted the need to measure and constantly improve quality in our healthcare system. Infectious Diseases (ID) physicians’ impact the quality of healthcare both at patients’ bedside but also through their infection prevention and antimicrobial stewardship activities that are focused on improving quality at the systems-level.
The resources below are designed to help ID physicians understand the current state of quality improvement and the transition towards a value driven healthcare system that publicly reports providers performance and pays for high quality outcomes.
Public Comment Opportunities
No public comment opportunities at this moment.
Quality Improvement Measure Concepts
As publisher of clinical practice guidelines and other guidance, IDSA has taken a leadership role in generating concepts for quality improvement measures specific to the best practices associated with the treatment of infectious diseases.
Available measure concepts:
- Staphylococcus aureus Measures Set
- Appropriate Use of Anti-MRSA Antibiotics
- Guideline Recommended Treatment of Clostridioides difficile Infection (CDI)
Please fill out the form below to download and view the measure concepts.
The measure concepts include numerator, denominator, exclusion statement, and supporting body of evidence for each measure.
We are open to productive collaboration with hospital systems, payers, and other health care stakeholders.
As the healthcare payment system continues to shift towards value-based reimbursement, the IDSA Quality Improvement Committee (QIC) will continue to report and support the development of ID-specific measures that demonstrate the value of ID physicians in performing quality improvement activities. In 2018, the QIC published an article, reporting the current MIPS measures related to antibotic administration, vaccination and diagnosis of infections in adults. However, the MIPS measures lack metrics that guide payers on the value of ID specialty care. The article discusses the benefits of evaluating ID specific measures through a Qualified Clinical Data Registry to satisfy MIPS reporting; and the development of measures from guideline-based management of patients with infectious diseases. In order to accurately report quality improvement activites that demonstrate the value of ID specialty care to payers, we reccomend developing a mix of patient-level outcomes and process-level measures.